No specific treatment is known. Management is supportive. Research into the efficacy of a subgroup of medications known as JAK inhibitors is underway.
STING-associated vasculopathy with onset in infancy
Livedoid vasculitis
Congenital hereditary endothelial dystrophy
Lupus vasculitis
Golfer's vasculitis
Systemic vasculitides
Roussy–Lévy syndrome
Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations